Esophageal Adenocarcinoma Clinical Trials

34 studies are recruiting for esophageal adenocarcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

   This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a sui…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Oncology Institute of Hope and Innovation, Cerritos, California

   Locations

   105 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06324357 on ClinicalTrials.gov

2. Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

   The goal of this clinical trial is to develop a method to detect Barrett's esophagus in individuals with a new office based diagnostic test. Barrett's esophagus is a condition in which the flat pink lining of the swallowing tube that connects the mouth to the stomach (the esophagus) becomes damaged…

   Stage

   Not phased

   Ages

   50 and older

   Site

   University of Colorado, Aurora, Colorado

   Locations

   5 in total

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT06687603 on ClinicalTrials.gov

3. Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

   This phase II trial tests how well itraconazole works in combination with the usual standard of care endoscopy with ablation for the prevention of esophageal cancer in patients who have high-risk Barrett's esophagus (BE). BE is a condition in which the lining of the esophagus changes and becomes mo…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Michigan Rogel Cancer Center, Ann Arbor, Michigan

   Locations

   6 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06732388 on ClinicalTrials.gov

4. A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma

   The purpose of this study is to find out whether adding the drug 2141-V11 to standard treatment (anti-PD-1 immunotherapy with or without 5-FU) is a safe treatment approach for participants with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07818018 on ClinicalTrials.gov

5. Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

   The purpose of this study is to learn the best approach to treating patients with known or suspected Barrett's esophagus by comparing endoscopic surveillance to endoscopic eradication therapy. To diagnose and manage Barrett's esophagus and low-grade dysplasia, doctors commonly use procedures called…

   Stage

   Not phased

   Ages

   18 to 89

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   30 in total

   Run by

   University of Colorado, Denver

   See if you can join NCT05753748 on ClinicalTrials.gov

6. A Study of KK2269 in Adult Participants With Solid Tumors

   This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary obje…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Arizona, Scottsdale, Arizona

   Locations

   32 in total

   Run by

   Kyowa Kirin Co., Ltd.

   See if you can join NCT06266299 on ClinicalTrials.gov

7. Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

   This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of the upper gastrointestinal (GI) tract and undetectable ctDNA at the time…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Smilow Cancer Center, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT07282912 on ClinicalTrials.gov

8. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

   The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   31 in total

   Run by

   Pfizer

   See if you can join NCT07090499 on ClinicalTrials.gov

9. A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

   This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor [CAR] T), in adult participants with advanced gastrointestinal (GI) cancers. The study will consist of 2 p…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   5 in total

   Run by

   Dispatch Biotherapeutics

   See if you can join NCT07544589 on ClinicalTrials.gov

10. Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

    The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based combinations in in participants with human epidermal growth factor receptor 2 (HER2)-Negative, unresectable, recurrent, a…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    12 in total

    Run by

    Gilead Sciences

    See if you can join NCT07546812 on ClinicalTrials.gov

11. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

    This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Normunity Investigational Site, Denver, Colorado

    Locations

    18 in total

    Run by

    Normunity AccelCo, Inc.

    See if you can join NCT07182149 on ClinicalTrials.gov

12. Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma

    This research study is for people who have locally advanced esophageal adenocarcinoma and are expected to receive chemotherapy. The purpose of this study is to compare the effectiveness of Liquid Nitrogen Spray Cryotherapy (LNSC) in addition to chemotherapy versus chemotherapy alone in the treatmen…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Cleveland Clinic Florida, Weston, Florida

    Run by

    Case Comprehensive Cancer Center

    See if you can join NCT07222657 on ClinicalTrials.gov

13. Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

    This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Rocky Mountain Cancer Centers, LLP, Aurora, Colorado

    Locations

    74 in total

    Run by

    Pfizer

    See if you can join NCT07392892 on ClinicalTrials.gov

14. Obeticholic Acid for Prevention in Barrett's Esophagus

    This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to neoplastic progression in Barrett's esophagus. Obeticholic acid has shown anti-cholestatic, anti-inflammatory and anti-fibroti…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Kansas Cancer Center, Kansas City, Kansas

    Locations

    8 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT04939051 on ClinicalTrials.gov

15. ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

    This is a proof of principle clinical trial determining efficacy of single dose dualimmune checkpoint inhibitors to increase intra-tumoral T cells in esophageal, gastroesophageal junction, and gastric adenocarcinomas. These are subjects who have not previously been treated for their disease, who ar…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT06824363 on ClinicalTrials.gov

16. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Alaska Oncology and Hematology, Anchorage, Alaska

    Locations

    158 in total

    Run by

    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT04389632 on ClinicalTrials.gov

17. Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

    The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area transepithelial sampling (WATS3D). Barrett's esophagus is a common condition that …

    Stage

    Not phased

    Ages

    18 to 89

    Site

    Arizona Centers of Digestive Health, Gilbert, Arizona

    Locations

    14 in total

    Run by

    University of Colorado, Denver

    See if you can join NCT05530343 on ClinicalTrials.gov

18. Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

    The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers. The study will collect biospecimens and clinical in…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT07675967 on ClinicalTrials.gov

19. Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

    Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which current standard of care treatment for their stage of disease would…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Dan Zandberg

    See if you can join NCT04114136 on ClinicalTrials.gov

20. Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

    This is an open label, phase II, multi-site trial evaluating the efficacy and safety of the combination of 5-FU, oxaliplatin, nal-IRI, and immunotherapy (plus trastuzumab for HER2-positive tumors) as first-line therapy for participants with advanced Esophageal and Gastric Adenocarcinoma (EGA). The …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT04150640 on ClinicalTrials.gov

21. First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

    A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, appro…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Scottsdale, Arizona

    Locations

    10 in total

    Run by

    Plexium, Inc.

    See if you can join NCT07284186 on ClinicalTrials.gov

22. Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples

    This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devices combined with markers for BE/esophageal adenocarcinoma (…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    Mayo Clinic, Scottsdale, Arizona

    Locations

    5 in total

    Run by

    Mayo Clinic

    See if you can join NCT06071845 on ClinicalTrials.gov

23. Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

    The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma). It will also help the researchers to learn more about the safety of givastomig. The main questions it aims to answer…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    I-Mab Site 1016, Goodyear, Arizona

    Locations

    6 in total

    Run by

    I-Mab Biopharma US Limited

    See if you can join NCT07432295 on ClinicalTrials.gov

24. Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

    The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. The main question it aims to answer is whether this combination is safe and effective in this ty…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York

    Locations

    2 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT06340711 on ClinicalTrials.gov

25. Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

    The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Diwakar Davar

    See if you can join NCT07223424 on ClinicalTrials.gov